Source: Rare Disease and Orphan Drug Journal Abstract One of the main challenges in rare diseases is the unavailability of reliable estimates of prevalence and
Source: PRWeb The cost of patients dropping out of clinical trials continues to be a major problem for the development of new drugs and treatments
Patients’ directly reported outcomes in certain rare and chronic diseases are considered reliable for understanding the disease’s natural history, palliative treatments that focus primarily on
Source: Healthcare Weekly Almost everything went online due to the COVID-19 pandemic, from remote collaboration with coworkers to ordering groceries and conducting online classes. But
Source: Pharmaceutical Outsourcing The outbreak of the COVID-19 pandemic seriously disrupted new drug testing, treatments, and in-person healthcare services; access to clinical trial sites was
Evidence linking interventions with health outcomes is vital for healthcare decision-making. Making sound choices about healthcare requires the best possible and quality evidence from clinical
Feb 3, 2021 By Harsha Rajasimha, Ph.D. & Sharlene Brown, Ph.D. Patient groups can optimize patient registries, cross-sectional studies, and/or longitudinal natural history studies to
